Cosmos Health Inc (NASDAQ: COSM) is a pharmaceutical and nutraceutical company that develops, manufactures, and distributes generic medicines, over-the-counter pharmaceutical products, branded nutraceuticals, and biocides primarily across European Union member states. Revenue is generated through direct sales of pharmaceutical products to pharmacies and wholesale drug distributors, who in turn supply hospitals, other wholesalers, and governmental agencies. No single customer accounted for 10% or more of total consolidated revenues during the years ended December 31, 2025 and December 31, 2024, indicating a distributed customer base. The company operates through subsidiaries including Cosmofarm S.A., its wholesale distribution arm. Product lines span branded nutraceuticals under the Sky Premium Life label, biocides under the C-Sept and C-Scrub brands, and specialty pharmaceutical products including Melatonin Spray, Otikon, and Bio-bebe. Cosmos Health also holds two patented anticancer drug candidates approaching Phase I clinical trials and has acquired the AI-driven drug repurposing platform Cloudscreen. The company is headquartered in Greece and carries a debt-heavy capital structure, funding operations partly through convertible notes and an at-the-market equity program.

Revenue model

Transactional product sales of generic pharmaceuticals, OTC drugs, branded nutraceuticals, and biocides to pharmacies and wholesale drug distributors under Ex-Works terms; no post-sale product liability assumed by the company. Capital also raised through ATM equity issuances ($5.4M gross proceeds, September 22 to December 31, 2025) and senior secured convertible promissory notes ($9.8M aggregate gross proceeds, year ended December 31, 2025).

Products and services

Generic medicines; OTC pharmaceutical products; branded nutraceuticals under the Sky Premium Life label covering immune health, cardiovascular health, amino acids, bones and joints, herbal extracts, men's and women's health, beauty, digestive health, brain health, sports and fitness, mood and sleep, detox, and urinary health; proprietary biocides C-Sept (C-Sept Pro 2% with 76% isopropyl alcohol and 2% chlorhexidine digluconate) and antiseptic soap C-Scrub Wash 4% CHG; specialty pharmaceuticals including Melatonin Spray, Otikon, and Bio-bebe; two patented anticancer therapies (WIPO patents WO 2017/001439A1 and WO 2018/011414A1) in pre-Phase I stage; obesity and weight management drug candidate CCX0722; gastrointestinal treatment CCDL24; CNS, prostate, ovarian, and colorectal cancer treatment candidates; AI-driven drug repurposing platform Cloudscreen.

Customers and end markets

Pharmaceutical wholesalers and retail healthcare providers (pharmacies) across EU member states; a limited number of large wholesale drug distributors who resell to hospitals, other wholesalers, and governmental agencies. No customer accounted for 10% or more of total consolidated revenues in FY2025 or FY2024. Sales are concentrated among a relatively small number of pharmaceutical wholesalers despite no single-customer concentration above 10%.

Value-chain role

Vertically integrated pharmaceutical company acting as manufacturer, branded product developer, and wholesale distributor. Sells on Ex-Works basis, transferring transportation risk to customers at point of sale. Operates automated warehouse technology and electronic purchase order and invoicing systems. Conducts in-house and contracted R&D including agreements with the National Hellenic Research Foundation and third-party oncology contractors.

Geographic exposure

Primarily European Union member states; patent filings targeting future commercialization in the USA, EU, Canada, Japan, China, and Australia.

Source: SEC 10-K, filed 2026-04-15

Industry: Wholesale-Drugs, Proprietaries & Druggists' Sundries Peers: ACRO Biomedical Co Ltd Fuse Medical Inc Great Elm Group Inc RedHawk Holdings Corp. McKesson Corp